Michelle MBA - Telomir Pharmaceuticals, Chief Officer
| TELO Stock | 4.91 0.03 0.61% |
Executive
Michelle MBA is Chief Officer of Telomir Pharmaceuticals, Common
| Age | 52 |
| Address | 100 SE 2nd St., Miami, FL, United States, 33131 |
| Phone | 813 864 2558 |
| Web | https://telomirpharma.com |
Telomir Pharmaceuticals, Management Efficiency
The company has return on total asset (ROA) of (2.0469) % which means that it has lost $2.0469 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.5269) %, meaning that it created substantial loss on money invested by shareholders. Telomir Pharmaceuticals,'s management efficiency ratios could be used to measure how well Telomir Pharmaceuticals, manages its routine affairs as well as how well it operates its assets and liabilities. As of the 18th of December 2024, Return On Tangible Assets is likely to drop to -2.88. In addition to that, Return On Capital Employed is likely to grow to -1.09. At this time, Telomir Pharmaceuticals,'s Total Assets are very stable compared to the past year. As of the 18th of December 2024, Non Current Assets Total is likely to grow to about 5.2 M, while Other Assets are likely to drop (44.7 K).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| David Boyer | Neurocrine Biosciences | 45 | |
| Christina Siniscalchi | Alvotech | N/A | |
| Darin Esq | Neurocrine Biosciences | 58 | |
| Dov Bergwerk | Teva Pharma Industries | N/A | |
| Bjorn Timelin | Haleon plc | N/A | |
| Ed Petter | Haleon plc | N/A | |
| Ingrid Delaet | Neurocrine Biosciences | 58 | |
| Eric Benevich | Neurocrine Biosciences | 59 | |
| Ran Meir | Teva Pharma Industries | N/A | |
| David JD | Teva Pharma Industries | 61 | |
| Matthew Shields | Teva Pharma Industries | 50 | |
| Haywood Miller | Emergent Biosolutions | N/A | |
| Placid Jover | Teva Pharma Industries | N/A | |
| Advocate Baron | Teva Pharma Industries | N/A | |
| Vikki Conway | Teva Pharma Industries | 52 | |
| Jane Sorensen | Neurocrine Biosciences | N/A | |
| Coleen Glessner | Emergent Biosolutions | 53 | |
| Simon MD | Emergent Biosolutions | N/A | |
| MBA MPH | Amphastar P | N/A | |
| MP MBA | Amphastar P | N/A | |
| William Hartzel | Emergent Biosolutions | N/A | |
Management Performance
| Return On Equity | -17.53 | ||||
| Return On Asset | -2.05 |
Telomir Pharmaceuticals, Leadership Team
Elected by the shareholders, the Telomir Pharmaceuticals,'s board of directors comprises two types of representatives: Telomir Pharmaceuticals, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Telomir. The board's role is to monitor Telomir Pharmaceuticals,'s management team and ensure that shareholders' interests are well served. Telomir Pharmaceuticals,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Telomir Pharmaceuticals,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christos Esq, General Director | ||
| MD Chapman, Chairman CoFounder | ||
| Nathen CPA, Treasurer, CFO | ||
| Itzchak Angel, Chief Advisor | ||
| Michelle MBA, Chief Officer | ||
| MD ODonnell, Chief Cofounder | ||
| Erez Aminov, Chairman CEO |
Telomir Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Telomir Pharmaceuticals, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -17.53 | ||||
| Return On Asset | -2.05 | ||||
| Current Valuation | 147.08 M | ||||
| Shares Outstanding | 29.75 M | ||||
| Shares Owned By Insiders | 42.66 % | ||||
| Shares Owned By Institutions | 6.90 % | ||||
| Number Of Shares Shorted | 650.6 K | ||||
| Price To Book | 332.47 X | ||||
| EBITDA | (11.43 M) | ||||
| Net Income | (13.07 M) |
Pair Trading with Telomir Pharmaceuticals,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Telomir Pharmaceuticals, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Telomir Pharmaceuticals, will appreciate offsetting losses from the drop in the long position's value.Moving against Telomir Stock
| 0.64 | ALVO | Alvotech | PairCorr |
| 0.57 | BMY | Bristol Myers Squibb | PairCorr |
| 0.56 | GILD | Gilead Sciences | PairCorr |
| 0.46 | XAIR | Beyond Air | PairCorr |
| 0.39 | CAH | Cardinal Health | PairCorr |
The ability to find closely correlated positions to Telomir Pharmaceuticals, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Telomir Pharmaceuticals, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Telomir Pharmaceuticals, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Telomir Pharmaceuticals, Common to buy it.
The correlation of Telomir Pharmaceuticals, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Telomir Pharmaceuticals, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Telomir Pharmaceuticals, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Telomir Pharmaceuticals, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telomir Pharmaceuticals, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Telomir Pharmaceuticals,. If investors know Telomir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Telomir Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.78) | Return On Assets (2.05) | Return On Equity (17.53) |
The market value of Telomir Pharmaceuticals, is measured differently than its book value, which is the value of Telomir that is recorded on the company's balance sheet. Investors also form their own opinion of Telomir Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is Telomir Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Telomir Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect Telomir Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Telomir Pharmaceuticals,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Telomir Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telomir Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.